NCT01832532View on ClinicalTrials.gov

A Pilot Study of the Effects on Sleep Disordered Breathing (SDB) When Using the Drug Liraglutide for 4 Weeks

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

December 31, 2015

Study Completion Date

December 31, 2015

Conditions
Sleep ApneaSleep Disordered Breathing
Interventions
DRUG

liraglutide

daily use of drug. Titrated up from 0.6mg/day to 1.8mg/day or highest tolerated dose

Trial Locations (1)

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

All Listed Sponsors
collaborator

National Center for Research Resources (NCRR)

NIH

lead

Children's Hospital Medical Center, Cincinnati

OTHER

NCT01832532 - A Pilot Study of the Effects on Sleep Disordered Breathing (SDB) When Using the Drug Liraglutide for 4 Weeks | Biotech Hunter | Biotech Hunter